Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 10/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | TYK2 | P29597 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559730 | 0.84 | ADORA2A (0.43) | ADORA2ANPC1RAB9A | |
| SCHEMBL560381 | 0.82 | ADORA2A (0.40) | GRIN2BADORA2ACYP2D6CYP2C9CYP3A4 | |
| SCHEMBL559333 | 0.82 | ADORA2A (0.49) | GRIN2BADORA2ACSF1R | |
| SCHEMBL559655 | 0.81 | ADORA2A (0.44) | GRIN2BADORA2ACYP2D6CYP2C9CYP3A4 | |
| SCHEMBL559355 | 0.80 | ADORA2A (0.41) | ADORA2ACYP2C9CYP3A4CYP2C19 | |
| SCHEMBL560112 | 0.80 | ADORA2A (0.44) | ADORA2ACYP2C9CYP2C19 | |
| SCHEMBL559478 | 0.78 | ADORA2A (0.44) | GRIN2BADORA2ACYP2C9CYP2C19NPC1 | |
| SCHEMBL559641 | 0.78 | ADORA2A (0.42) | GRIN2BADORA2ANPC1RAB9A | |
| SCHEMBL14393438 | 0.77 | ADORA2A (0.57) | ADORA2A | |
| SCHEMBL10456428 | 0.77 | ADORA2A (0.57) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309774-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2012-12-06 | — | — | US | disclosed |
| US-20120035192-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2012-02-09 | — | — | US | disclosed |
| US-7985754-B2 | Selective antagonists of A2A adenosine receptors | TROVIS PHARMACEUTICALS, LLC (US) | 2011-07-26 | — | — | US | disclosed |
| US-20090118309-A1 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2009-05-07 | — | — | US | disclosed |
| EP-2041136-A2 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | PGXHealth, LLC (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008011007-A2 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | PGXHEALTH, LLC (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309774-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADORA2A, ADORA3, ADORA2B | GRIN2B 394/4885ADORA2A 1/4885CYP2D6 701/4885 |
| US-20090118309-A1 | Selective antagonists of A2A adenosine receptors | ADORA2A, ADORA3, ADORA2B | GRIN2B 394/4885ADORA2A 1/4885CYP2D6 701/4885 |
| US-20120035192-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADORA2A, ADORA3, ADORA2B | GRIN2B 394/4885ADORA2A 1/4885CYP2D6 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.